Salicyn-30 (Anti-viral – STI 2030)
Since the beginning of the COVID-19 pandemic, Sorrento has developed a program targeting the entire continuum of care (for prevention, early treatment and rescue therapies) to manage COVID-19 disease. It is Sorrento’s belief that multi-modal therapies will naturally follow the approval of effective single therapies, regardless of individual drug potential.
Our latest discovery in the Sorrento COVID-19 Program includes Salicyn-30 anti-viral that strongly inhibits SARS-CoV-2 infection in preclinical studies and highlights its place in a potential multi-modal therapy in combination with neutralizing antibodies against COVID.
Salicyn-30 will be developed initially as a stand-alone oral therapy to potentially reduce viral load in severely affected patients. In parallel, its potential in combination with Sorrento’s potent STI-1499 and affinity matured STI-2020 neutralizing antibodies currently in development will be validated, both for synergistic efficacy but also to ensure that the safety of the combination therapy is established prior to human trials.